



## **Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines**

### **Reflect Scientific, Inc.**

1266 South 1380 West

Orem, Utah 84058

801-226-4100

reflectscientific.com

info@reflectscientific.com

## **Quarterly Report**

**For the Period Ending: June 30, 2025**  
(the "Reporting Period")

### **Outstanding Shares**

The number of shares outstanding of our Common Stock was:

85,664,086 as of June 30, 2025

85,664,086 as of December 31, 2024

### **Shell Status**

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes:  No:

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes:  No:

### **Change in Control**

Indicate by check mark whether a Change in Control<sup>4</sup> of the company has occurred during this reporting period:

Yes:  No:

---

<sup>4</sup>"Change in Control" shall mean any events resulting in:

- (i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

**1) Name and address(es) of the issuer and its predecessors (if any)**

In answering this item, provide the current name of the issuer and names used by predecessor entities, along with the dates of the name changes.

Reflect Scientific, Inc., a Utah corporation (the "Company," "we," "our," "us" and words of similar import), was organized under the laws of the State of Utah on November 3, 1999, under the name "Cole, Inc." ("Cole"). On December 31, 2003, we acquired Reflect Scientific, Inc., a California corporation "Reflect California". We changed our name to "Reflect Scientific, Inc.," ceased the then current business operations of Cole, a start-up company engaged in providing Edgar filing and related services and we succeeded to the business operations of our new wholly-owned subsidiary, Reflect California, which involved the manufacture and distribution of unique laboratory consumables and disposables such as filtration and purification products, customized sample handling vials, electronic wiring assemblies, high temperature silicone, graphite and vespel/graphite sealing components for use by original equipment manufacturers ("OEM") in the chemical analysis industries, primarily in the field of gas/liquid chromatography.

On November 29, 2005, we announced the execution of a Letter of Intent to acquire Cryomastor Corporation, a California corporation ("Cryomastor" [sometimes called "Cryometrix," its amended name]).

Effective as of April 4, 2006, we entered into a Purchase Agreement (the "JMST Agreement") with JM SciTech, LLC, a limited liability company organized under the laws of the State of Colorado, and doing business as "JMST Systems" ("JMST"); David Carver, an individual ("Carver"); and Julie Martin, an individual ("Martin") (JMST, Carver and Martin are sometimes hereinafter referred to collectively as the "Sellers"). Pursuant to the JMST Agreement, we purchased and JMST sold all right, title and interest in and to the JMST Technology (the "JMST Technology"), as described in the JMST Agreement; and Carver conveyed and assigned any rights he had in and to certain patents (the "Carver Patents") and related intellectual assets as described in the JMST Agreement (collectively, including the Carver Patents, referred to herein as the "Carver Technology"). JMST had created a line of chemical detection instruments that are used in the pharmaceutical, biotechnology and homeland security markets. The patented technology allows researchers to accurately analyze chemical formulations for their composition and identity.

On June 27, 2006, we completed the acquisition of Cryomastor pursuant to an Agreement and Plan of Merger (the "Cryomastor Merger Agreement"), which became our wholly-owned subsidiary; changed its name to "Cryometrix, Inc."; and succeeded to its business operations, which involved the manufacture and sale of ultra-low temperature freezer systems powered by liquid nitrogen for use in bio-repositories associated with the biotech and pharmaceutical industries, as well as government facilities, universities and many other diverse applications that require a large number of reliable and energy efficient freezers.

Current State and Date of Incorporation or Registration: Utah, November 3, 1999.

Standing in this jurisdiction: (e.g. active, default, inactive): Current.

Prior Incorporation Information for the issuer and any predecessors during the past five years:

None.

Describe any trading suspension or halt orders issued by the United States Securities and Exchange Commission (the "SEC") or the Financial Industry Regulatory Authority ("FINRA") concerning the issuer or its predecessors since inception:

None.

List any stock split, dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None.

Address of the issuer's principal executive office:

1266 South 1380 West, Orem, Utah 84058

Address of the issuer's principal place of business:

*Check if principal executive office and principal place of business are the same address:*

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No:  Yes:  If Yes, provide additional details below:

## 2) Security Information

### **Transfer Agent**

Name: Direct Transfer LLC  
Phone: 919-343-9941  
Email: info@issuerdirect.com  
Address: One Glenwood Ave., Suite 101  
Raleigh, NC 27603

### **Publicly Quoted or Traded Securities:**

*The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.*

Trading symbol:	RSCF	
Exact title and class of securities outstanding:	Common	
CUSIP:	758 66F 101	
Par or stated value:	\$0.01	
Total shares authorized:	100,000,000	<u>as of date: June 30, 2025</u>
Total shares outstanding:	85,664,086	<u>as of date: June 30, 2025</u>
Total number of shareholders of record:	107	<u>as of date: June 30, 2025</u>

*Please provide the above-referenced information for all other publicly quoted or traded securities of the issuer.*

None.

### **Other classes of authorized or outstanding equity securities that do not have a trading symbol:**

*The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g., preferred shares that do not have a trading symbol). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.*

Exact title and class of the security:	Preferred	
Par or stated value:	\$0.01	
Total shares authorized:	5,000,000	<u>as of date: June 30, 2025</u>
Total shares outstanding:	0	<u>as of date: June 30, 2025</u>
Total number of shareholders of record:	0	<u>as of date: June 30, 2025</u>

Please provide the above-referenced information for all other classes of authorized or outstanding equity securities.

None.

**Security Description:**

*The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:*

**1. For common equity, describe any dividend, voting and preemption rights.**

The Company is authorized to issue 100,000,000 shares of common stock having a par value of \$0.01 per share.

Holders of our common stock are entitled to one vote per share with respect to each matter presented to our stockholders on which the holders of common stock are entitled to vote. Subject to the rights of the holders of any preferred stock we may designate or issue in the future, or as may otherwise be required by law or our Articles of Incorporation, our common stock is our only common stock entitled to vote in the election of directors and on all other matters presented to our stockholders. The common stock does not have cumulative voting rights or preemptive rights. Subject to the prior rights of holders of preferred stock, if any, holders of our common stock are entitled to receive dividends as may be lawfully declared from time to time by our Board of Directors. Upon our liquidation, dissolution or winding up, whether voluntary or involuntary, holders of our common stock will be entitled to receive such assets as are available for distribution to our stockholders after there shall have been paid, or set apart for payment, the full amounts necessary to satisfy any preferential or participating rights to which the holders of any outstanding series of preferred stock are entitled.

**2. For preferred stock, describe the dividend, voting, conversion and liquidation rights as well as redemption or sinking fund provisions.**

Our Board of Directors is authorized to issue preferred stock in one or more series and, with respect to each series, to determine the preferences, rights, qualifications, limitations and restrictions thereof, including the dividend rights, conversion rights, voting rights, redemption rights and terms, liquidation preferences, sinking fund provisions, the number of shares constituting the series and the designation of such series.

We had previously authorized and issued a Series A Preferred Stock. All shares issued under the Series A Preferred Stock were subsequently converted into shares of common stock, and there are no shares of preferred stock outstanding.

**3. Describe any other material rights of common or preferred stockholders.**

None.

**4. Describe any material modifications to rights of holders of the Company's securities that have occurred over the reporting period covered by this report.**

None.

### 3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period**.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

#### A. Changes to the Number of Outstanding Shares for the two most recently completed fiscal years and any subsequent period.

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No:  Yes:  (If yes, you must complete the table below)

Shares Outstanding <u>Opening Balance</u> : Date December 31, 2022 Common: <u>85,214,086</u> Preferred: 0			*Right-click the rows below and select "Insert" to add rows as needed.						
Date of Transaction	Transaction type (e.g., new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to.  ***You must disclose the control person(s) for any entities listed.	Reason for share issuance (e.g. for cash or debt conversion) - OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
<u>12/29/2023</u>	<u>New issuance</u>	<u>450,000</u>	<u>Common</u>	<u>\$0.08</u>	<u>No</u>	<u>BAO Tran (1)</u>	<u>Services - Patent Attorney</u>	<u>Yes</u>	<u>None</u>
---	---	---	---	---	---	---	---	---	---
---	---	---	---	---	---	---	---	---	---
Shares Outstanding on Date of This Report: <u>Ending Balance</u> : Date June 30, 2025 Common: <u>85,664,086</u> Preferred: 0									

**Example:** A company with a fiscal year end of December 31<sup>st</sup> 2024, in addressing this item for its Annual Report, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2023 through December 31, 2024 pursuant to the tabular format above.

**\*\*\*Control persons for any entities in the table above must be disclosed in the table or in a footnote here.**

Use the space below to provide any additional details, including footnotes to the table above:

(1) BAO Tran is owned 100% by Bao Tran, who is a Patent Attorney and provided patent services.

**B. Convertible Debt**

The following is a complete list of the Company’s Convertible Debt which includes all promissory notes, convertible notes, convertible debentures, or any other debt instruments convertible into a class of the issuer’s equity securities. The table includes all issued or outstanding convertible debt at any time during the last complete fiscal year and any interim period between the last fiscal year end and the date of this Certification.

Check this box to confirm the Company had no Convertible Debt issued or outstanding at any point during this period.

Date of Note Issuance	Principal Amount at Issuance (\$)	Outstanding Balance (\$)  (include accrued interest)	Maturity Date	Conversion Terms (e.g., pricing mechanism for determining conversion of instrument to shares)	# Shares Converted to Date	# of Potential Shares to be Issued Upon Conversion <sup>5</sup>	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g., Loan, Services, etc.)

Total Outstanding Balance:

Total Shares:

Any additional material details, including footnotes to the table are below:

None.

**4) Issuer’s Business, Products and Services**

The purpose of this section is to provide a clear description of the issuer’s current operations. Ensure that these descriptions are updated on the Company’s Profile on [www.OTCMarkets.com](http://www.OTCMarkets.com).

A. Summarize the issuer’s business operations (If the issuer does not have current operations, state “no operations”)

**Overview**

We are engaged in the manufacture and distribution of innovative products targeted at the life science market. Our customers include hospitals, diagnostic laboratories, pharmaceutical and biotech companies, cold chain management, universities, government and private sector research facilities, chemical and industrial companies.

<sup>5</sup>The total number of shares that can be issued upon full conversion of the Outstanding Balance. The number should not factor any “blockers” or limitations on the percentage of outstanding shares that can be owned by the Noteholder at a particular time. For purposes of this calculation, please use the current market pricing (e.g. most recent closing price, bid, etc.) of the security if conversion is based on a variable market rate.

Our goal is to provide our customers with the best solution for their needs. This philosophy extends into our business strategies and acquisition plans. Through a series of strategic acquisitions, we acquired technology that has enabled us to expand our line of products to align with, and capitalize on, market needs. Our growing product portfolio includes ultra-low temperature freezers, blast freezers, solvent chillers and refrigerated transportation in addition to supplying OEM products to the life sciences industry.

Our Cryometrix brand ultra-low temperature and blast freezers innovative design enables our customers to save substantially on energy costs related to cryogenic storage. Ultra-low temperature freezers are used worldwide for the storage of vaccines, DNA, RNA, proteins and many other biological and chemical substances. There is a growing need for energy efficient, reliable ultra-low temperature storage units. Our Cryometrix freezers are targeted to this growing market and we have had tremendous success in blood storage and pharmaceutical manufacturing applications. The application of this technology for use in refrigerated trailers (commonly called "reefers") used to transport goods which need to be maintained in a cold environment significantly broadens the market for this technology. The utilization of this technology in reefers eliminates the current method of cooling, which uses engines run on hydrocarbon fuels. The Cryometrix technology is pollutant free and is more efficient and cost effective than the technologies currently used. Reflect Scientific has added a new product line of solvent chillers. Solvent chillers are used in natural products extraction for optimizing product yield and purity.

B. List any subsidiaries, parent company, or affiliated companies.

Reflect Scientific, Inc., a Utah corporation.

C. Describe the issuers' principal products or services.

We design, develop and sell scientific equipment for the life sciences and manufacturing industries. Since Reflect Scientific's inception in 1993, our focus is and has been on providing value added products, analytic testing supplies and equipment, and stand-alone products for the life sciences and industrial marketplace. Reflect Scientific's products range from non-mechanical Cryometrix™ freezers and value-added products and components for the life sciences industry to tools and analytical services for industrial manufacturing.

Our Cryometrix freezers use an entirely different technology for cooling that requires far less power and has significantly fewer moving parts. Less power consumption and fewer parts (i.e., less chance for wear or malfunction) translates into an immediate realization of cost savings to the customer. Management believes that there is no mechanical freezer that can match the temperature uniformity and rapid cooling of our Cryometrix freezer. These attributes are why these freezers are being sold into the pharmaceutical market – they meet customer needs that cannot be fulfilled by current freezer technology.

All of Reflect Scientific's products and services are developed with one key factor in mind: Providing a superior cost/benefit to the customer versus other products in the same market space. With years of experience in the life science and industrial manufacturing markets, Reflect Scientific has been able to develop not only unique patentable products, but products that we believe offer a superior value proposition to the customer.

We have developed a business model with a focus on excellence in the design and development of products and solutions for life science and industrial manufacturing industries. We outsource the majority of our manufacturing, allowing us to concentrate our efforts on product innovation across multiple lines and industries. Our strength is in developing and providing value added products which we believe offer immediate and verifiable benefits and cost saving solutions.

We have found a number of companies that can manufacture products to our specification, allowing us to focus on our core competencies of development and design, and maintain a flexible corporate structure capable of taking advantage of new opportunities without the large capital investment required to acquire tooling and manufacturing equipment. Our focus on development and design expertise, as opposed to

manufacturing of products, enables us to innovate along multiple industry lines and customize our products to meet specific needs in a variety of industrial settings. Our products are sold in the biotechnology, natural products, pharmaceutical, cold chain management and medical industries, as well as manufacturing industries, such as automotive.

### Cryometrix Freezers

Our Cryometrix ultra-low temperature and blast freezers are, we believe, a technological breakthrough that provides energy savings and other critically important benefits to cryo-storage customers in the life science related industries. Ultra-low temperature and blast freezers are used in many applications for the storage and fast freezing protocols of everything from blood to cancer vaccines. These types of freezers are used by hospitals and biotechnology research facilities.

The only ultra-low temperature freezers currently available are produced by a limited number of companies and rely on a mechanical process for cooling. Because of inadequacies in the mechanical process, we believe there is loss of inventory each year because of the problems related to reliability inherent with mechanical freezers.

Our freezers incorporate a disruptive technology. They are based on a complete divergence from the technology currently used in ultra-low temperature freezers. Through the advantages of our technology, we believe our freezers solve the current inadequacies and provide immediate cost savings and reliability for our clients. Current cryogenic storage equipment falls short of customer expectations in a variety of key performance criteria.

- \* High energy usage – a growing problem with rising energy costs;
- \* Inflexible temperature range control– existing units cannot be easily modified for colder requirements (colder temperatures are an industry trend);
- \* Sample inventory is at risk in the event of a power failure;
- \* Poor temperature uniformity –samples in different areas of the freezer can experience wide variations in temperatures which is undesirable from a regulatory standpoint; and
- \* Frost build-up.

Our Cryometrix ultra low temperature and blast freezer uses a patented design and technology which is powered by liquid nitrogen. Through the use of a liquid nitrogen powered freezer system we are able to address the market need for:

- \* Low energy requirements;
- \* Flexible temperature control – wide range of usable temperatures;
- \* Power failures have little effect - uses passive liquid nitrogen technology rather than electrically powered compressors;
- \* Uniform temperatures throughout freezer – more usable storage volume;
- \* Much larger storage volume per area of floor space occupied – reduced facilities cost;
- \* Reliable and essentially maintenance free, further lowering cost of ownership; and
- \* Environmental issues related to pollution using the current refrigerated trailer (“reefer”) technology.

Cryometrix freezers are powered by liquid nitrogen. Our competition’s freezers, including those developed by Thermo Fisher Scientific and Sanyo Corporation, are compressor based, with hydrofluorocarbon (“HFC”) refrigerants and electric compressors. This basic technology difference results in the following Cryometrix advantages:

- \* The Cryometrix freezer cooling medium is nitrogen, an all-green element that makes up 78% of our atmosphere, while many competitors use refrigerants that are harmful to the environment;
- \* Cryometrix freezers cool extremely fast compared to the competition and one particular Cryometrix freezer will cool to -80C in eight minutes, an order of magnitude faster than the competition;

\* The inherent Cryometrix technology provides a much more uniform temperature throughout the freezer than competitors' compressor-based freezers;

\* When power is lost, our competitors' freezers immediately fail to operate, while Cryometrix freezers, when placed in manual freezing mode, continue to maintain a cold temperature for days and even weeks; and

\* Cryometrix freezers are more reliable than the competition; those well-versed in mean time between failure analysis calculate potential failures mainly based on the number of moving parts; and Compressor-based freezers have many moving parts and are not as reliable in theory or in practice as Cryometrix freezers, which have almost no moving parts.

The adaptation of the freezer technology to reefers for transporting perishable items opens a significant new market. Trailers can easily be retrofitted with the Cryometrix unit, which operates pollution free, more efficiently, and provides a cost savings compared to the diesel-powered units currently used. The non-polluting Cryometrix unit provides significant benefits over any other unit currently marketed.

A new development using a similar liquid nitrogen cooling technology is the solvent chiller. Solvent chillers are used for providing chilled solvent for extracting a final commercial product from plant materials. The extraction solvent is rapidly chilled to a temperature that will optimize the extraction purity and recovery of the final product of interest. Solvent chillers are currently being sold into the CBD extraction market.

#### Other Products

In addition to our Cryometrix freezers, we market our Visacon OEM products, LCGCVials.com vial products, GCFerules.com OEM GC consumable products and HPLC Detectors.com UV detector products into the chromatography market. These are highly technical products and encompass a vast array of sizes, configurations and uses. These products represent a stable supplies business but they do not represent a significant growth opportunity for the Company.

### **5) Issuer's Facilities**

*The goal of this section is to provide investors with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.*

In responding to this item, please clearly describe the assets, properties or facilities of the issuer. Describe the location of office space, data centers, principal plants, and other property of the issuer and describe the condition of the properties. Specify if the assets, properties, or facilities are owned or leased and the terms of their leases. If the issuer does not have complete ownership or control of the property, describe the limitations on the ownership.

Reflect Scientific conducts all of its business operations from one facility, located in Orem, Utah. This is a combination warehouse and office facility with 6,000 square feet of space. As of June 30, 2025, we lease this facility at \$8,395 per month (with semi-annual rent increases) through the end of the lease term on November 30, 2026.

### **6) All Officers, Directors, and Control Persons of the Company**

Using the table below, please provide information, as of the period end date of this report, regarding all officers and directors of the Company, or any person that performs a similar function, regardless of the number of shares they own.

In addition, list all individuals or entities controlling 5% or more of any class of the issuer's securities. If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity. Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

*The goal of this section is to provide investors with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial owners.*

Names of All Officers, Directors, and Control Persons	Affiliation with Company (e.g. Officer Title /Director/Owner of 5% or more)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Names of control person(s) if a corporate entity
Kim Boyce	President and Director	Provo, Utah	43,637,250	Common	50.9%	NA
Tom Tait	Vice President, Secretary and Director	Box Elder, South Dakota	900,000	Common	1.1%	NA
William Moon	Director	Provo, Utah	1,100,000	Common	1.3%	NA

Confirm that the information in this table matches your public company profile on [www.OTCMarkets.com](http://www.OTCMarkets.com). If any updates are needed to your public company profile, log in to [www.OTCIQ.com](http://www.OTCIQ.com) to update your company profile.

## 7) Legal/Disciplinary History

A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years:

1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);

None.

2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;

None.

3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;

None.

4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or

None.

5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

None.

6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

None.

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party to or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None.

### 8) Third Party Service Providers

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

Confirm that the information in this table matches your public company profile on [www.OTCMarkets.com](http://www.OTCMarkets.com). If any updates are needed to your public company profile, update your company profile.

Securities Counsel (must include Counsel preparing Attorney Letters).

Name: Leonard W. Burningham  
Address 1: P.O. Box 521844  
Address 2: Salt Lake City, Utah 84152-1844  
Phone: (801) 363-7411  
Email: [lwb@burninglaw.com](mailto:lwb@burninglaw.com)

#### Accountant or Auditor

Name: Kristi Kampmann  
Firm: NOWCFO  
Address 1: 1800 Wazee Street, 3rd Floor  
Address 2: Denver, CO 80202  
Phone: 1-888-697-4724  
Email: [denverinfo@nowcfo.com](mailto:denverinfo@nowcfo.com)

#### Investor Relations

Name: \_\_\_\_\_  
Firm: \_\_\_\_\_  
Address 1: \_\_\_\_\_  
Address 2: \_\_\_\_\_  
Phone: \_\_\_\_\_  
Email: \_\_\_\_\_

*All other means of Investor Communication:*

X (Twitter): \_\_\_\_\_

Discord: \_\_\_\_\_  
LinkedIn \_\_\_\_\_  
Facebook: \_\_\_\_\_  
[Other ] \_\_\_\_\_

### Other Service Providers

Provide the name of any other service provider(s) that **assisted, advised, prepared, or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Name: Shelley Goff  
Firm:  
Nature of Services: Preparation services for Annual and Quarterly OTC Disclosure Statements  
Address 1: 2598 Canyon View Drive  
Address 2: Santa Clara, Utah 84765  
Phone: (435) 656-5188  
Email: shelley@burninglaw.com

### **9) Disclosure & Financial Information**

A. This Disclosure Statement was prepared by (name of individual):

Name: Kim Boyce  
Title: President  
Relationship to Issuer: Officer

B. The following financial statements were prepared in accordance with:

- IFRS  
 U.S. GAAP

C. The following financial statements were prepared by (name of individual):

Name: Jill Mendivil  
Title: VP of Finance  
Relationship to Issuer: Employee

Describe the qualifications of the person or persons who prepared the financial statements:<sup>5</sup>

Jill Mendivil has over 30 years of experience in financial management. Since 2020, as VP of Finance at Reflect Scientific, Inc., she oversees accounts payable (AP), accounts receivable (AR), and payroll, as well as prepares quarterly and yearly financials, and collaborates with external auditors. She also manages the preparation and filing of SEC reports, including 10-Q and 10-K. Jill has extensive experience in payroll, tax documentation, financial management, and SEC reporting and has handled accounts payable, accounts receivable, company cash flow, bank statements, government payments and collections throughout her career.

Provide the following qualifying financial statements:

- Audit letter, if audited;

\_\_\_\_\_

<sup>5</sup>The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

- Balance Sheet;
- Statement of Income;
- Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- Statement of Cash Flows;
- Financial Notes

**Financial Statement Requirements:**

- Financial statements must be published together with this disclosure statement as one document.
- Financial statements must be “machine readable”. Do not publish images/scans of financial statements.
- Financial statements must be presented with comparative financials against the prior FYE or period, as applicable.
- Financial statements must be prepared in accordance with U.S. GAAP or International Financial Reporting Standards (IFRS) but are not required to be audited.

**REFLECT SCIENTIFIC, INC.**  
CONDENSED CONSOLIDATED BALANCE SHEETS

<u>ASSETS</u>	June 30, 2025 (Unaudited)	December 31, 2024 Unaudited)
<b>Current Assets</b>		
Cash and cash equivalents	\$ 1,299,380	\$ 1,014,421
Accounts receivable, net	184,648	321,001
Inventories, net	716,329	720,070
Prepaid expenses and other current assets	10,955	31,491
Total Current Assets	2,211,312	2,086,983
Operating lease right-of-use assets	123,641	162,776
Goodwill	60,000	60,000
Other long-term assets	3,100	3,100
Total Assets	\$ 2,398,053	\$ 2,312,859
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
<b>Current Liabilities</b>		
Accounts payable and accrued expenses	\$ 54,478	\$ 71,264
Customer deposits	90,927	-
Current portion of operating leases liabilities	94,704	83,467
Total Current Liabilities	240,109	154,731
Operating lease liabilities, net of current portion	46,263	96,497
TOTAL LIABILITIES	286,372	251,228
<b>Stockholders' Equity</b>		
Preferred Stock, \$0.01 par value, 5,000,000 shares authorized; none issued and outstanding as of June 30, 2025 and December 31, 2024	-	-
Common stock, \$0.01 par value, 100,000,000 shares authorized; 85,664,086 shares issued and outstanding as of June 30, 2025 and December 31, 2024	856,640	856,640
Additional paid-in capital	20,302,681	20,302,681
Accumulated deficit	(19,047,639)	(19,097,691)
TOTAL STOCKHOLDERS' EQUITY	2,111,682	2,061,630
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$ 2,398,053	\$ 2,312,859

*The accompanying notes are an integral part of these condensed unaudited consolidated financial statements.*

**REFLECT SCIENTIFIC, INC.**  
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2025	2024	2025	2024
Revenues	\$ 279,867	\$ 590,071	\$ 648,353	\$ 1,018,826
Cost of goods sold	99,690	231,514	222,316	418,480
Gross profit	180,178	358,557	426,037	600,346
<b>Operating Expenses</b>				
Salaries and wages	103,373	148,054	207,043	290,668
General and administrative	89,104	107,555	177,994	239,859
Research and development	3,456	4,605	9,215	11,980
Total Operating Expenses	195,933	260,214	394,252	542,507
<b>INCOME (LOSS) FROM OPERATIONS</b>	<b>(15,755)</b>	<b>98,343</b>	<b>31,785</b>	<b>57,839</b>
Other Income (Expense)	9,876	10,644	18,266	19,177
<b>NET INCOME (LOSS) BEFORE INCOME TAXES</b>	<b>(5,879)</b>	<b>108,987</b>	<b>50,051</b>	<b>77,016</b>
INCOME TAX EXPENSE	-	-	-	-
<b>NET INCOME (LOSS)</b>	<b>\$ (5,879)</b>	<b>\$ 108,987</b>	<b>\$ 50,051</b>	<b>\$ 77,016</b>
<b>Loss per common share</b>				
Basic and diluted	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.00
<b>Weighted average shares outstanding</b>				
Basic and diluted	85,664,086	85,664,086	85,664,086	85,664,086

*The accompanying notes are an integral part of these condensed unaudited consolidated financial statements.*

**REFLECT SCIENTIFIC, INC.**  
**CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)**

Six Months Ended June 30, 2025

	Common Shares		Additional Paid-In Capital	Accumulated Deficit	Total Stockholders' Equity
	Shares	Amount			
Balance at December 31, 2024	85,664,086	\$ 856,640	\$ 20,302,681	\$ (19,097,691)	\$ 2,061,630
Net Income	-	-	-	55,930	55,930
Balance at March 31, 2025	85,664,086	\$ 856,640	\$ 20,302,681	\$ (19,041,761)	\$ 2,117,560
Net Loss	-	-	-	(5,879)	(5,879)
Balance at June 30, 2025	85,664,086	\$ 856,640	\$ 20,302,681	\$ (19,047,640)	\$ 2,111,681

Six Months Ended June 30, 2024

	Common Shares		Additional Paid-In Capital	Accumulated Deficit	Total Stockholders' Equity
	Shares	Amount			
Balance at December 31, 2023	85,664,086	\$ 856,640	\$ 20,302,681	\$ (19,266,747)	\$ 1,892,574
Net loss	-	-	-	(31,971)	(31,971)
Balance at March 31, 2024	85,664,086	\$ 856,640	\$ 20,302,681	\$ (19,298,718)	\$ 1,860,603
Net income	-	-	-	108,987	108,987
Balance at June 30, 2024	85,664,086	\$ 856,640	\$ 20,302,681	\$ (19,189,731)	\$ 1,969,590

*The accompanying notes are an integral part of these condensed unaudited consolidated financial statements.*

**REFLECT SCIENTIFIC, INC.**  
**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)**

	For the Six Months Ended June 30,	
	2025	2024
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>		
Net income (loss)	\$ 50,051	\$ 77,016
Adjustments to reconcile net loss to net cash used in operating activities:		
Amortization of right-of-use assets	39,135	35,627
Changes in operating assets and liabilities:		
Accounts receivable	136,353	(2,401)
Inventories	3,741	136,626
Prepaid expenses and other current assets	20,536	2,835
Accounts payable and accrued expenses	(16,786)	(33,338)
Customer deposits	90,927	(357,075)
Operating lease liabilities	(38,997)	(28,876)
Net cash (used in) provided by operating activities	<u>284,960</u>	<u>(175,255)</u>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>		
Net cash provided by investing activities	<u>-</u>	<u>-</u>
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Net cash provided by financing activities	<u>-</u>	<u>-</u>
<b>NET CHANGE IN CASH AND CASH EQUIVALENTS</b>	<b>284,960</b>	<b>(175,255)</b>
<b>CASH AND CASH EQUIVALENTS</b>		
Beginning of the period	1,014,421	1,277,951
End of the period	<u>\$ 1,299,380</u>	<u>\$ 1,102,696</u>
<b>SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION</b>		
Cash paid for interest	\$ -	\$ -
Cash paid for income taxes	\$ -	\$ -

*The accompanying notes are an integral part of these condensed unaudited consolidated financial statements.*

**REFLECT SCIENTIFIC, INC.**  
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
JUNE 30, 2025  
(UNAUDITED)

**NOTE 1—BASIS OF PRESENTATION AND OTHER INFORMATION**

Reflect Scientific, Inc. (the “Company”) was incorporated under the laws of the State of Utah on November 3, 1999 as Cole, Inc. The Company was organized to engage in any lawful activity for which corporations may be organized under the Utah Revised Business Corporation Act. On December 30, 2003, the Company changed its name to “Reflect Scientific, Inc.”

The Company is engaged in the manufacture and distribution of innovative products targeted at the life sciences market. Our customers include hospitals, diagnostic laboratories, pharmaceutical and biotech companies, cold chain management, universities, government and private sector research facilities, chemical and industrial companies.

*Interim Financial Statements*

These unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). The unaudited consolidated financial statements include the accounts of all consolidated subsidiaries and financially controlled variable interest entities. All intercompany balances and transactions have been eliminated in consolidation. The interim unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2024, included in the Annual Disclosure Statement. In the opinion of management, all adjustments considered necessary for a fair presentation of the financial statements, consisting solely of normal recurring adjustments, have been made. Operating results for the six and three months ended June 30, 2025, are not necessarily indicative of the results that may be expected for the year ending December 31, 2025.

*Use of Estimates*

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

*Cash and Cash Equivalents*

Cash and cash equivalents consist of cash on hand and marketable securities with original maturities of three months or less. The Company maintains deposits in several financial institutions, which may at times exceed amounts covered by insurance provided by the U.S. Federal Deposit Insurance Corporation (“FDIC”). The Company has not experienced any losses related to amounts in excess of FDIC limits.

*Revenue Recognition*

The Company records revenue in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 606, “Revenue from Contracts with Customers.” Revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, the Company applies the following five-step approach: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to performance obligations in the contract; and (5) recognize revenue when or as a performance obligation is satisfied.

We sell our specialty science and environmental lab supplies through direct sales and through distributor relationships. We sell our ultra- low temperature freezers through consultants and commission-only sales personnel. Revenue is recognized at a point in time when control of the promised goods or services is transferred to the customer, generally at the time of shipment or customer acceptance, in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. This core principle is achieved through the following steps:

Identify the contract with the customer. A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party’s rights regarding the goods to be transferred and identifies the payment terms related to these goods, (ii) the contract has commercial substance and, (iii) we determine that collection of substantially

all consideration for services that are transferred is probable based on the customer's intent and ability to pay the promised consideration.

Identify the performance obligations in the contract. Generally, our contracts with our laboratory supply customers do not include multiple performance obligations to be completed over a period of time. Our performance obligations generally relate to delivering specialty laboratory products to a customer, subject to the shipping terms of the contract.

Ultra-low temperature freezers sold to customers are built to order. Generally, 50% of the value of the contract is paid by the customer prior to work beginning on manufacturing the freezer. Upon completion of manufacturing and testing the customer will then sign an acceptance of the unit and make payment of the remaining balance on the contract, at which title passes to the customer. The customer may either arrange to transport the unit with a carrier he uses or ask the Company to arrange such shipment, the charges of which are the responsibility of the customer. A customer may, after accepting the unit, request that it be upgraded with additional hardware or software options. Those options are installed under a new contract, with the deposit and final payment requirements being the same as on the original order.

Any warranty obligations associated with the sale of our products are assurance-type warranties that are a guarantee of the product's intended functionality and, therefore, do not represent a distinct performance obligation within the context of the contract. We do not typically offer extended warranty or service plans.

Determine the transaction price. The transaction price is determined based on the consideration that the Company is entitled to receive in exchange for transferring the goods or services to the customer. The Company includes in the transaction price an amount of variable consideration only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Variable considerations including discounts and estimated returns, are deducted from gross sales in determining net sales at the time revenues are recorded. Historically, we have not had any significant returns.

Allocate the transaction price to performance obligations in the contract. We typically do not have multiple performance obligations in our laboratory supply contracts with customers. As such, we generally recognize revenue upon transfer of the product to the customer's control at contractually stated pricing. The freezers likewise do not have milestone or percentage of completion clauses in the contract, so revenue is only recognized when the work has been completed.

Recognize revenue when or as we satisfy a performance obligation. We generally satisfy performance obligations at a point in time upon either shipment or, with our freezers, upon final acceptance of the unit by the customer, in accordance with the terms of each contract with the customer. We do not have significant service revenue.

We have elected to use the practical expedient in ASC 340 (regarding recognition of the incremental costs of obtaining a contract) and expense any costs of obtaining a contract as incurred as our contracts are typically completed in one year or less.

We do require customer deposits to be made on freezer purchases when an order is placed. The deposits are recognized as revenue when our performance obligation is completed, or they are refunded by the Company in the event of an order cancellation. The Company does not assess whether a significant financing component exists if the period between when the Company performs its obligations under the contract and when the customer pays is one year or less. As of June 30, 2025 and December 31, 2024, we had customer deposits of \$90,927 and \$0, respectively.

### ***Inventories***

The Company's inventory consists of parts for scientific vial kits, refrigerant gases, components for the imaging and inspection systems which it builds, and other scientific items. The Company values inventory at each balance sheet date to ensure that it is carried at the lower of cost or net realizable value with cost determined based on the average cost basis. The Company periodically evaluates the value of items in inventory and provides write-downs to inventory based on its estimate of market conditions. As of June 30, 2025 and December 31, 2024, the estimated reserve for obsolescence amounted to \$106,044 respectively.

### ***Leases***

The Company accounts for leases in accordance with ASC Topic 842, "Leases." The Company determines whether a contract is a lease at contract inception or for a modified contract at the modification date. At inception or modification, the Company recognizes ROU assets and related lease liabilities on the balance sheet for all leases greater than one year in duration. Lease liabilities and their corresponding ROU assets are initially measured at the present value of the unpaid lease payments as of the lease commencement date. If the lease contains a renewal and/or termination option, the exercise of the option is included in the term of the lease if the Company is reasonably certain that a renewal or

termination option will be exercised. As the Company's leases do not provide an implicit rate, the Company uses an estimated incremental borrowing rate ("IBR") based on the information available at the commencement date of the respective lease to determine the present value of future payments. The IBR is determined by estimating what it would cost the Company to borrow a collateralized amount equal to the total lease payments over the lease term based on the contractual terms of the lease and the location of the leased asset.

Operating lease payments are recognized as an expense on a straight-line basis over the lease term in equal amounts of rent expense attributed to each period during the term of the lease, regardless of when actual payments are made. This generally results in rent expense in excess of cash payments during the early years of a lease and rent expense less than cash payments in later years. The difference between rent expense recognized and actual rental payments is typically represented as the spread between the ROU asset and lease liability.

When calculating the present value of minimum lease payments, we account for leases as one single lease component if a lease has both lease and non-lease fixed cost components. Variable lease and non-lease cost components are expensed as incurred.

We do not recognize ROU assets and lease liabilities for short-term leases that have an initial lease term of 12 months or less. We recognize the lease payments associated with short-term leases as an expense on a straight-line basis over the lease term.

### ***Earnings (Loss) Per Share***

Basic earnings (loss) per share is calculated by dividing net income (loss) by the weighted average number of shares of common stock outstanding during each period. Diluted earnings per share is calculated by adjusting the weighted average number of shares of common stock outstanding for the dilutive effect, if any, of common stock equivalents. Common stock equivalents whose effect would be antidilutive are not included in diluted earnings (loss) per share. The Company uses the treasury stock method to determine the dilutive effect, which assumes that all common stock equivalents have been exercised at the beginning of the period and that the funds obtained from those exercises were used to repurchase shares of common stock of the Company at the average closing market price during the period.

### ***Research and Development***

The Company accounts for research and development costs in accordance with ASC Topic 730 "*Research and Development*." Under the provisions of ASC 730, research and development costs are expensed as incurred. As of the six months ended June 30, 2025 and 2024, research and development costs amounted to \$9,215 and \$11,980, respectively.

### ***Recently Issued Accounting Pronouncements***

In November 2023, the FASB issued ASU 2023-07, "*Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures*," which requires a public entity to disclose significant segment expenses and other segment items on an annual and interim basis and to provide in interim periods all disclosures about reportable segment's profit or loss and assets that are currently required annually. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. These amendments are to be applied retrospectively. The Company is currently evaluating the impact this standard will have on its unaudited condensed consolidated financial statements.

In December 2023, the FASB issued ASU 2023-09, "*Income Taxes (Topic 740): Improvements to Income Tax Disclosures*," which enhances the transparency and decision usefulness of income tax disclosures by requiring; (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. ASU 2023-09 is effective for fiscal years beginning after December 15, 2025, with early adoption permitted. These amendments are to be applied prospectively, with retrospective application permitted. The Company is currently evaluating the impact this standard will have on its unaudited condensed consolidated financial statements.

The Company currently believes there are no other issued and not yet effective accounting standards that are materially relevant to our unaudited condensed consolidated financial statements.

## NOTE 2—DISAGGREGATION OF REVENUES

Our revenue is disaggregated based on product category and geographical region. We recognize revenue from the sale of scientific equipment for the life sciences and manufacturing industries. Our products include non-mechanical Cyrometrix freezers, chillers, and original equipment manufacturer (“OEM”) value-added products and components for the life sciences industry.

The Company’s revenues for the three months ended June 30, 2025 and 2024 are disaggregated as follows:

	For the Three Months Ended June 30, 2025		
	United States	International	Total
Revenues			
Freezers and chillers	\$ 133,060	\$ 2,796	\$ 135,856
OEM and other	109,241	34,769	144,010
Total Revenues	\$ 242,301	\$ 37,565	\$ 279,866

	For the Three Months Ended June 30, 2024		
	United States	International	Total
Revenues			
Freezers and chillers	\$ 391,198	\$ -	\$ 391,198
OEM and other	159,385	39,488	198,873
Total Revenues	\$ 550,583	\$ 39,488	\$ 590,072

The Company’s revenues for the six months ended June 30, 2025 and 2024 are disaggregated as follows:

	Six Months Ended June 30, 2025		
	United States	International	Total
Revenues			
Freezers and chillers	\$ 146,044	\$ 121,844	\$ 267,888
OEM and other	305,357	75,107	380,464
Total Revenues	\$ 451,401	\$ 196,951	\$ 648,352

	Six Months Ended June 30, 2024		
	United States	International	Total
Revenues			
Freezers and chillers	\$ 655,468	\$ -	\$ 655,468
OEM and other	297,181	66,177	363,358
Total Revenues	\$ 952,649	\$ 66,177	\$ 1,018,826

## NOTE 3—INVENTORIES

Inventories at June 30, 2025 and December 31, 2024 consisted of the following:

	June 30, 2025	December 31, 2024
Finished goods	\$ 606,301	\$ 610,181
Raw materials	216,072	215,933
Total inventories	822,373	826,114
Less reserve for obsolescence	(106,044)	(106,044)
Total inventories, net	\$ 716,329	\$ 720,070

Inventory balances are composed of finished goods and raw materials. Work in process inventory is immaterial to the unaudited condensed consolidated financial statements.

## NOTE 4—LEASES

The following was included in our condensed consolidated balance sheets at June 30, 2025 and December 31, 2024:

	June 30, 2025	December 31, 2024
Operating lease right-of-use assets	\$ 123,641	\$ 162,776
Lease liabilities, current portion	94,704	83,467
Lease liabilities, long-term	46,263	96,497
Total operating lease liabilities	\$ 140,967	\$ 179,964
Weighted-average remaining lease term (months)	17	23
Weighted average discount rate	10.50%	10.50%

Total lease expense for the three and six months ended June 30, 2025 and 2024 is as follows:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2025	2024	2025	2024
Operating lease expense	\$ 23,875	\$ 23,875	\$ 47,750	\$ 47,750
Variable lease expense	-	-	-	-
Total lease expense	\$ 23,875	\$ 23,875	\$ 47,750	\$ 47,750

Cash payments included in the measurement of our operating lease liabilities were \$24,802 and \$20,777 for the three months ended and \$47,613 and \$41,002 for the six months ended June 30, 2025 and 2024, respectively. Pursuant to the terms of the lease, in June 2025 base rent increased from \$7,844 to \$8,395 per month.

As of June 30, 2025, maturities of operating lease liabilities were as follows:

Year Ending December 31,	Amount
2025	\$ 50,919
2026	101,708
2027	-
Total	152,627
Less: imputed interest	(11,661)
Total operating lease liabilities	\$ 140,966

## NOTE 5—STOCKHOLDERS' EQUITY

### *Preferred Stock*

In November 2004 the Company amended its Articles of Incorporation so as to authorize 5,000,000 shares of preferred stock. Of this total, 750,000 shares have been designated as "Series A Convertible Preferred Stock".

The following is a description of the rights of the Series A Convertible Preferred Stock:

**Dividends.** The holders of the Series A Preferred Stock would be entitled to dividends at the rate of eight percent per year of the liquidation preference of \$1.00 per share, payable annually, if and when declared by the board of directors. Dividends are not cumulative, and the board of directors is under no obligation to declare dividends.

**Conversion Rights.** The Series A Preferred Stock may be convertible into the Company's common stock by dividing \$1.00 plus any unpaid dividends by 50% of the five day average closing bid price of the common shares.

As of June 30, 2025, the Company had no shares of the preferred stock issued and outstanding.

### *Common Stock*

As of June 30, 2025 and December 31, 2024, the Company was authorized to issue 100,000,000 common shares, of which 85,664,086 common shares were issued and outstanding.

***Potential Common Stock Equivalents***

As of June 30, 2025, and December 31, 2024, there were no potential common share equivalents from restricted stock awards.

**NOTE 6 -SUBSEQUENT EVENTS**

In accordance with ASC 855 – *Subsequent Events*, the Company has analyzed its operations after June 30, 2025 and did not identify any transactions as subsequent events.

## 10) Issuer Certification

### *Principal Executive Officer:*

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Kim Boyce certify that:

1. I have reviewed this Disclosure Statement for Reflect Scientific, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

August 13, 2025

/s/Kim Boyce

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

### *Principal Financial Officer:*

I, Kim Boyce certify that:

1. I have reviewed this Disclosure Statement for Reflect Scientific, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

August 13, 2025

/s/Kim Boyce

(Digital Signatures should appear as "/s/ [OFFICER NAME]")